Advertisement

The Effect of Indomethacin on Renal Function and Glomerular Protein Loss

  • Ab J. Donker

Abstract

In 1955 Fieschi and Bianchi published the paper “Il fenilbutazone: Un farmaco attivo sulla albuminuria,” in which they described their experiences with phenylbutazone in patients with proteinuria. A decrease in protein excretion and an increase in plasma albumin concentration were observed in 21 out of 25 patients with the nephrotic syndrome.1 Also the late Professor J. G. G. Borst did extensive research at that time in Amsterdam on the effects of phenylbutazone and aminophenazone in patients with adrenocorticotropic hormone- (ACTH) resistant nephrotic syndrome. He noticed that the decrease in urinary protein loss induced by these drugs was often associated with a decrease in the clearance of creatinine.2 Serious side effects of phenylbutazone and aminophenazone, however, ultimately limited both general application in and longterm treatment of patients with steroid-resistant severe proteinuria.

Keywords

Nephrotic Syndrome Sodium Restriction Effective Renal Plasma Flow Sodium Depletion Antiproteinuric Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fieschi A, Bianchi V: Il fenilbutazone: Un farmaco attivo sulla albuminuria. Prog Med Napoli 9: 257, 1955.Google Scholar
  2. 2.
    Vries LA de, ten Holt SP, van Daatselaar JJ, et al: Characteristic renal excretion patterns in response to physiological, pathological and pharmalogical stimuli. Clin Chim Acta 5: 915, 1960.Google Scholar
  3. 3.
    Shen TY, Windholtz TB, Rosegay A, et al: Nonsteroid anti-inflammatory agents. J Am Chem Soc 85: 488, 1963.CrossRefGoogle Scholar
  4. 4.
    Winter CA, Risley EA, Nuss GW: Anti-inflammatory and antipyretic activities of indomethacin, 1(para-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid. J Pharamcol Exp Ther 141: 369, 1963.Google Scholar
  5. 5.
    Norcross BM, Latona SR: Treatment of rheumatic diseases with indomethacin. Arthritis Rheum. 6: 290, 1963.Google Scholar
  6. 6.
    Rothermich NO: An extended study of indomethacin. I. Clinical pharmacology. J Am Med Assoc 195: 531, 1966.CrossRefGoogle Scholar
  7. 7.
    Michielsen P, Lambert PP: Effets du traitement par les corticostéroides et l’indométhacine sur la protéinurie. Bull Mem. Soc. Med. Hop. Paris 118: 217, 1967.PubMedGoogle Scholar
  8. 8.
    Santopadre I, Comellini L: Prime esperienze sull’impiego dell’indomethacin in alcune nefropatie dell’infanzia. Clin Pediatr 48: 229, 1966.Google Scholar
  9. 9.
    Conté J, Suc JM, Mignon-Conté M: Effet anti-protéinurique de l’indométhacine dans les glomérulopathies. J Urol Nephrol 73: 850, 1967.Google Scholar
  10. 10.
    Michielsen P, Verberckmoes R, Desmet V, et al: Evolution histologique des glomérulonéphrites prolifératives diffuses traitées par l’indométhacine. J Urol Nephrol 75: 315, 1969.Google Scholar
  11. 11.
    Conté J, Mignon-Conté M, Moreau G, et al: Les anti-inflammatoires ont-ils une efficacité réelle dans le traitement des néphropathies glomérulaires?, in Actualités Néphrologiques de l’Hôpital Necker. Paris, Flammarion, 1970, p 313.Google Scholar
  12. 12.
    Wijdeveld PGAB: Some clinical and therapeutic aspects of the nephrotic syndrome in the adult (with special emphasis on the effects of indomethacin and related substances). Folia Med Neerl 14: 4, 1971.PubMedGoogle Scholar
  13. 13.
    Lagrue G, Bariéty J, Druet P, et al: Le traitement des glomérulopathies primitives par une substance antiinflammatoire: l’indométhacine. Ann Med Intern Paris 122: 77, 1971.Google Scholar
  14. 14.
    Michielsen P, Vanrenterghem Y, Verberckmoes R, et al: Does anti-inflammatory drug treatment modify the natural history of proliferative glomerulonephritis?, in Vlth International Congress on Nephrology, Florence, Italy, 1975,Abstract of Symposia pp 93–94.Google Scholar
  15. 15.
    Michielsen P, Vanrenterghem Y, Roels L: Treatment of chronic glomerulonephritis with indomethacin, in Kluthe R, Vogt A, Batsford SR (eds): Glomerulonephritis. International Conference on Pathogenesis, Pathology and Treatment. Stuttgart, Georg Thieme, 1976.Google Scholar
  16. 16.
    Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature London New Biol 231: 232, 1971.Google Scholar
  17. 17.
    Needleman P, Marshall GR, Douglas JR: Prostaglandin release from vasculature by angiotensin II: Dissociation from lipolysis. Eur J Pharmacol 23: 316, 1973.PubMedCrossRefGoogle Scholar
  18. 18.
    Donker AJM, Arisz L, Brentjens JRH, et al: The effect of indomethacin on kidney function and plasma renin activity in man. Nephron 17: 288, 1976.PubMedCrossRefGoogle Scholar
  19. 19.
    de Jong PE,, de Jong-van den Berg LTW, Sewrajsingh GS et al: The influence of indomethacin on renal haemodynamics in sickle cell anaemia. Clin Sci 59: 245, 1980.Google Scholar
  20. 20a.
    de Jong PE: Sickle cell nephropathy: New insights into its pathophysiology. Thesis. Drukkerij van Denderen B.V. Groningen, 1980.Google Scholar
  21. 20b.
    de Jong PE,, de Jong-van den Berg LTW, Donker AJM et al: The influence of indomethacin on renal concentrating and diluting capacity in sickle cell nephropathy. Clin Sci 63: 53, 1982.Google Scholar
  22. 21.
    Statius van Eps LW, Pinedo-Veels C,, de Vries GH et al: Nature of the concentration defect in sickle cell nephropathy: Microradiographic studies. Lancet 1: 450, 1970.PubMedCrossRefGoogle Scholar
  23. 22.
    Donker AJM, Prins E, Meijer S, et al: A renal function study in 30 patients on long-term lithium therapy. Clin Nephrol 12: 254, 1979.PubMedGoogle Scholar
  24. 23.
    Anderson RJ, Berl T, McDonald KM, et al: Evidence for an in vivo antagonism between vasopressin and prostaglandin in the mammalian kidney J Clin Invest 56: 420, 1975.PubMedCrossRefGoogle Scholar
  25. 24.
    Rutecki GW, Nally JV, Bay WH, et al: The acute effects of lithium (Li) on renal function. Kidney Int 12: 571, 1977.Google Scholar
  26. 25.
    Kirschenbaum MA, Serros ER: Effects of alteration in urine flow rate on prostaglandin E excretion in conscious dogs. Am J Physiol 238: F107, 1980.Google Scholar
  27. 26.
    Singer I: Lithium and the kidney. Kidney Int 19: 374, 1981.PubMedCrossRefGoogle Scholar
  28. 27.
    Miskind MH, Greenspan RE, Bay WH, et al: Studies on lithium-induced polyuria. Clin Res 25: 596A, 1977.Google Scholar
  29. 28.
    Arisz L, Donker AJM, Brentjens JRH, et al: The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand 199: 121, 1976.PubMedCrossRefGoogle Scholar
  30. 29.
    Donker AJM, Brentjens JRH, van der Hem GK, et al: Treatment of the nephrotic syndrome with indomethacin. Nephron 22: 374, 1978.Google Scholar
  31. 30.
    Lianos E, Alavi N, Venuto R, et al: Effects of prostaglandin inhibition on protein excretion and renal hemodynamics in patients with proteinuria. Kidney Int 19: 131, 1981.Google Scholar
  32. 31.
    Gribnau FWJ: Indomethacin in experimental nephritis. Thesis. Drukkerij Brakkenstein, Nijmegen, The Netherlands, 1975.Google Scholar
  33. 32.
    Baylis C, Brenner BM: The physiologic determinants of glomerular ultrafiltration. Rev Physiol Biochem Pharmacol 80: 1, 1978.PubMedGoogle Scholar
  34. 33.
    Data JL, Chang LCT, Nies AS: Alteration of canine renal vascular response to hemorrhage by inhibitors of prostaglandin synthesis. Am J Physiol 230: 940, 1976.PubMedGoogle Scholar
  35. 34.
    Baylis C, Brenner BM: Modulation by prostaglandin synthesis inhibitors of the action of exogenous angiotensin II on glomerular ultrafiltration in the rat. Circ Res 43: 889, 1978.Google Scholar
  36. 35.
    Boyer TD, Zia P, Reynolds TB: Effect of indomethacin and prostaglandin A, on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 77: 215, 1979.PubMedGoogle Scholar
  37. 36.
    Heymann MA, Rudolph AM, Silverman NH: Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. New Engl J Med 295: 530, 1976.PubMedCrossRefGoogle Scholar
  38. 37.
    Walshe JJ, Venuto RC: Acute oliguric renal failure induced by indomethacin: Possible mechanism. Ann Intern Med 91: 47, 1979.PubMedGoogle Scholar
  39. 38.
    Muther RS, Potter DM, Bennett WM: Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance. Ann Intern Med 94: 317, 1981.PubMedGoogle Scholar
  40. 39.
    Kimberley RP, Gill JR Jr, Bowden RE, et al: Elevated urinary prostaglandins and the effects of asperin on renal function in lupus erythematosus. Ann Intern Med 89: 336, 1978.Google Scholar
  41. 40.
    Kimberley RP, Bowden RE, Keiser HR, et al: Reduction of renal function by newer non-steroidal anti-inflammatory drugs. Am J Med 64: 804, 1978.CrossRefGoogle Scholar
  42. 41.
    Tiggeler RG, Hulme B, Wijdeveld PG: Effect of indomethacin on glomerular permeability in the nephrotic syndrome. Kidney Int 16: 312, 1979.PubMedCrossRefGoogle Scholar
  43. 42.
    Brenner BM, Bohrer MP, Baylis C, et al: Determinants of glomerular permselectivity: Insights dereived from observations in vivo. Kidney Int 12: 231, 1977.CrossRefGoogle Scholar
  44. 43.
    Baylis C, Deen WM, Myers BD, et al: Effects of some vasodilator drugs on transcapillary fluid exchange in the renal cortex. Am J Physiol 230: 1148, 1976.PubMedGoogle Scholar
  45. 44.
    Chang RLS, Ueki IF, Troy JL, et al: Permselectivity of the glomerular capillary wall to macromolecules. II. Experimental studies in rats using neutral dextran. Biophys J 15: 887, 1975.PubMedCrossRefGoogle Scholar
  46. 45.
    Myers BD, Deen WM, Brenner BM: Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 37: 101, 1975.Google Scholar
  47. 46.
    Hoomtje SJ, Weening JJ, Prins EJL, et al: Membranous glomerulopathy in a patient on captopril. Acta Med Scand 208: 325, 1980.Google Scholar
  48. 47.
    Medina A, Davies DL, Brown JJ, et al: A study on the renin—angiotensin system in the nephrotic syndrome. Nephron 12: 233, 1974.PubMedCrossRefGoogle Scholar
  49. 48.
    Dorhout Mees, EJ, Roos JC, Boer P, et al: Observations on edema formation in the nephrotic syndrome in adults with minimal lesions. Am J Med 67: 378, 1979.CrossRefGoogle Scholar
  50. 49.
    Mendrick D, Noble B, Brentjens J, et al: Antibody mediated injury to proximal tubules (PT) in Heymann nephritis (HN). Kidney Int 16: 799, 1979.Google Scholar
  51. 50.
    Noble B, Brentjens J, Andres G, et al: Damage to renal proximal tubules in rats with Heymann nephritis following reimmunization with Fx1A. Kidney Int 19: 188, 1981.Google Scholar
  52. 51.
    Caldwell PRB, Seegal BC, Hsu KC: Angiotensin-converting enzyme: Vascular endothelial localization. Science 191: 1050, 1976.PubMedCrossRefGoogle Scholar
  53. 52.
    Wigger Hi, Stalcup SA: Distribution and developement of angiotensin converting enzyme in the fetal and newborn rabbit. Lab Invest 38: 581, 1978.PubMedCrossRefGoogle Scholar
  54. 53.
    Carone FA, Pullman TN, Oparil S, et al: Micropuncture evidence of rapid hydrolysis of bradykinin by rat proximal tubule. Am J Physiol 230: 1420, 1976.PubMedGoogle Scholar
  55. 54.
    Vinci JM, Horwitz D, Zusman RM, et al: The effect of converting enzyme inhibition with SQ 20,881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man. Hypertension 1: 416, 1979.PubMedGoogle Scholar
  56. 55.
    Liebross BA, Serros ER, Nissenson AR, et al: Indomethacin (Indo)-induced reversal of severe proteinuria in rats with autologous immune complex nephropathy (AICN). Kidney Int 16: 785, 1979.Google Scholar

Copyright information

© Plenum Publishing Corporation 1983

Authors and Affiliations

  • Ab J. Donker
    • 1
    • 2
  1. 1.Academisch ZiekenhuisGroningenThe Netherlands
  2. 2.Afdeling InterneGroningenThe Netherlands

Personalised recommendations